Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates - 2Thousands of small fish defy gravity to climb Congo waterfall
- 3UK can legally stop shadow fleet tankers, ministers believe
- 4Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 5Chicago reports first rabies-positive dog in 61 years. What we know.
- Striking American and European television Projects: A Survey
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Vote in favor of the juice that you love for its medical advantages!
- Manual for Notorious Fragrances: Immortal Aromas
- The Specialty of Cleaning up: Change Your Space and Brain
- What is the Significant Tech Expertise to Master Today?
- Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
